Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1182-1193

  Kriegl, Lydia ^a   Vieth, Michael ^b   Kirchner, Thomas ^a   Menssen, Antje ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

BRAF and KRAS mutation; c MYC; Colorectal cancer; Serrated route; SIRT1

Indexed keywords

B RAF KINASE; BETA CATENIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; SIRTUIN 1;

ARTICLE; B RAF KINASE GENE; CANCER GRADING; CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; ONCOGENE C MYC; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIRTUIN 1 GENE; TRANSCRIPTION REGULATION; TUMOR GENE; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84872781106     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.628     Document Type: Article

References (52)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-532.
2. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-1512.
3. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011; 42(1):1-10.
4. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009; 4:343-364.
5. Rosenberg DW, Yang S, Pleau DC, Greenspan EJ, Stevens RG, Rajan TV, Heinen CD, Levine J, Zhou Y and O'Brien MJ. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 2007; 67(8):3551-3554.
6. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C and Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer. 2008; 8:255.
7. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, Arkan MC, Kirchner T and Greten FR. Ink4a/ Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell. 2010; 18(2):135-146.
8. Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ, Winton DJ, Marais R and Pritchard CA. V600EBRAF induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med. 2010; 2(11):458-471.
9. Torlakovic EE, Gomez JD, Driman DK, Parfitt JR, Wang C, Benerjee T and Snover DC. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol. 2008; 32(1):21-29.
10. O'Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am. 2007; 36(4):947-968, viii.
11. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, Larsson LG and Hermeking H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012; 109(4):E187-196.
12. Li L, Wang L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W and Bhatia R. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell. 2012; 21(2):266-281.
13. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG and Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. Embo J. 2002; 21(10):2383-2396.
14. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107(2):149-159.
15. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001; 107(2):137-148.
16. Brooks CL and Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009; 9(2):123-128.
17. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA and Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006; 66(8):4368-4377.
18. Liu T, Liu PY and Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009; 69(5):1702-1705.
19. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS and Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2009; 22(7):922-932.
20. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
21. Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009; 205(12):858-862.
22. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M and Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7(3):413-421.
23. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A and Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007; 203(7):489-497.
24. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H and Eimoto T. Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the sawtoothed structure may be related to inhibition of apoptosis. Am J Surg Pathol. 2002; 26(2):249-256.
25. Horkko TT and Makinen MJ. Colorectal proliferation and apoptosis in serrated versus conventional adenomacarcinoma pathway: growth, progression and survival. Scand J Gastroenterol. 2003; 38(12):1241-1248.
26. Komori K, Ajioka Y, Watanabe H, Oda K and Nimura Y. Proliferation kinetics and apoptosis of serrated adenoma of the colorectum. Pathol Int. 2003; 53(5):277-283.
27. Guerrero S, Casanova I, Farre L, Mazo A, Capella G and Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorageindependent growth than codon 13 mutation or protooncogene overexpression. Cancer Res. 2000; 60(23):6750-6756.
28. Yang S, Farraye FA, Mack C, Posnik O and O'Brien MJ. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol. 2004; 28(11):1452-1459.
29. Mitomi H, Sada M, Kobayashi K, Igarashi M, Mori A, Kanazawa H, Nishiyama Y, Ihara A and Otani Y. Different apoptotic activity and p21(WAF1/CIP1), but not p27(Kip1), expression in serrated adenomas as compared with traditional adenomas and hyperplastic polyps of the colorectum. J Cancer Res Clin Oncol. 2003; 129(8):449-455.
30. Huang J, Gan Q, Han L, Li J, Zhang H, Sun Y, Zhang Z and Tong T. SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS ONE. 2008; 3(3):e1710.
31. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y and Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006; 25(2):176-185.
32. Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, Liu DP and Liang CC. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol. 2011; 43(11):1573-1581.
33. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T, Mackenzie KL, Haber M, et al. SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability. PLoS Genet. 2011; 7(6):e1002135.
34. Yuan J, Minter-Dykhouse K and Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol. 2009; 185(2):203-211.
35. Menssen A and Hermeking H. c-MYC and SIRT1 locked in a vicious cycle. Oncotarget. 2012; 3(2):116-117. 36. Sears R, Leone G, DeGregori J and Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999; 3(2):169-179.
36. Sears R, Leone G, DeGregori J and Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999; 3(2):169-179.
37. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14(19):2501-2514.
38. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G and Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006; 21(4):509-519.
39. Gregory MA, Qi Y and Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003; 278(51):51606-51612.
40. Wu JM, Montgomery EA and Iacobuzio-Donahue CA. Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. Am J Clin Pathol. 2008; 129(3):416-423.
41. Yachida S, Mudali S, Martin SA, Montgomery EA and Iacobuzio-Donahue CA. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol. 2009; 33(12):1823-1832.
42. Jiao YF, Nakamura S, Sugai T, Yamada N and Habano W. Serrated adenoma of the colorectum undergoes a proliferation versus differentiation process: new conceptual interpretation of morphogenesis. Oncology. 2008; 74(3-4):127-134.
43. Fu X, Li J, Li K, Tian X and Zhang Y. Hypermethylation of APC promoter 1A is associated with moderate activation of Wnt signalling pathway in a subset of colorectal serrated adenomas. Histopathology. 2009; 55(5):554-563.
44. Finch AJ, Soucek L, Junttila MR, Swigart LB and Evan GI. Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/ beta-catenin pathway activation. Mol Cell Biol. 2009; 29(19):5306-5315.
45. Hermeking H and Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 1994; 265(5181):2091-2093.
46. Bond CE, Umapathy A, Ramsnes I, Greco SA, Zhen Zhao Z, Mallitt KA, Buttenshaw RL, Montgomery GW, Leggett BA and Whitehall VL. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int J Cancer. 2012; 130(7):1567-1576.
47. Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A and Kirchner T. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol. 2011; 24(7):1015-1022.
48. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR and Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol. 2003; 162(3):815-822.
49. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG and Baylin SB. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006; 2(3):e40.
50. Sasaki T, Maier B, Bartke A and Scrable H. Progressive loss of SIRT1 with cell cycle withdrawal. Aging Cell. 2006; 5(5):413-422.
51. Peng L, Yuan Z, Ling H, Fukasawa K, Robertson K, Olashaw N, Koomen J, Chen J, Lane WS and Seto E. SIRT1 Deacetylates the DNA Methyltransferase 1 (DNMT1) Protein and Alters Its Activities. Mol Cell Biol. 2011; 31(23):4720-4734.
52. Wang Z, Yuan H, Roth M, Stark JM, Bhatia R and Chen WY. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. 2012; Mar 12(doi:10.1038/onc.2012.83).